Functional connectivity of the prefrontal cortex and amygdala is related to depression status in major depressive disorder.

<bold>Background: </bold>We used resting-state functional magnetic resonance imaging to examine possible amygdala-prefrontal cortex functional connectivity abnormalities and to clarify the correlation of the abnormal connectivity with response to antidepressant medications.<bold>Methods: </bold>We recruited 40 drug-naïve patients with first-episode depression, had a 17-item Hamilton Rating Scale for Depression (HRSD17) score>17 for participation in a magnetic resonance imaging scan. Remission was defined as an HRSD17 score <7 following 8 weeks of fluoxetine antidepressant treatment. Gender- and age-matched healthy subjects (n = 26) also underwent MRI scanning. Finally, the association between the change in HRSD17 scores and a change in connectivity between the amygdala and prefrontal cortex from pre to post-treatment was evaluated in major depressive disorder (MDD).<bold>Results: </bold>After controlling for age, gender and years of education, a statistically significant increase in functional connectivity to the right prefrontal cortex from the amygdala was observed in the MDD group compared with the healthy control group (p<0.05, corrected). After 8 weeks of antidepressant treatment and remission in the MDD group, a significant decrease in functional connectivity to the right prefrontal cortex and the left prefrontal cortex from the amygdala was observed, compared with the level of connectivity in the drug-naïve MDD group(p<0.05,corrected). There were no significant associations between the difference in HRSD17 scores rMDD and fMDD with the change in connectivity.<bold>Limitations: </bold>The design of this study lack resistance to treatment for the depressed group.<bold>Conclusions: </bold>Increased functional connectivity of PFC-AMY is a promise to be a biomarker of MDD, however weather it could be a biomarker of fluoxetine treatment needs future studying. [ABSTRACT FROM AUTHOR]